The Success Of GLP-1s Could Cause A Boom In Medical Aesthetics Next

Mentioned:

GLP-1s have quickly become one the single most successful pharmaceutical products ever. And now, they might be causing a new boom in medical aesthetics.

What’s happening:

Multiple private and public companies have been investing in clinical research and new product development targeting the aesthetic effects caused by GLP-1 induced rapid weight loss

Why it matters:

McKinsey publicly stated in a research report that 63% of patients seeking facial aesthetics after GLP-1 weight loss were not previously active users of medical aesthetic treatments

Who is making moves:

South Korea’s L&C Bio is developing an injectable product known as MegaAdipoECM which is aiming to provide a biological scaffold into which the patient’s own cells can migrate into and repopulate the area to deal with facial volume loss and skin laxity from GLP-1 weight loss
Rapalogix Health raised a $20M USD Series A financing round to advance their skincare line and complete Investigation New Drug work for their aesthetic dermatology drug RLX-202
Pharmaceutical giant Galderma has made GLP-1 facial volume loss a meaningful research priority over the last year and a half and Chief Executive Officer Flemming Ornskov publicly stated that GLP-1 patients have started to provide an early boost to their aesthetics and injectables business
Conexeu Sciences (NASDAQ: CNXU) has publicly stated they are aiming to position their proprietary CXU platform for medical aesthetics and facial and body tissue restoration

Going deeper:

Conexeu Sciences just recently made waves when they successfully completed their 12 month preclinical study focused on evaluating their CXU platform as a potential tissue restoration solution for medical aesthetics and the knock on effects caused by GLP-1 weight loss drugs
The 12 month preclinical trial completed completed by Conexeu Sciences demonstrated that their CXU platform met its objective for tissue restoration in a facial model and is designed to be delivered through a fine-gauge needle for precise placement to support the tissue changes that can follow GLP-1 weight loss, including both facial volume loss as well as skin laxity

The intrigue:

The United States Food and Drug Administration has notably given Conexeu Sciences pre-submission feedback for their initial wound care indication

Disclaimer

The New Money provides background information on early stage companies from publicly available sources. The New Money provides no advice on dealing in securities, is not a financial adviser and does not pretend to be so. This message is meant for information and educational purposes only. The information contained in this article is not to be considered factual or complete. Anybody interested in obtaining financial and other information on companies mentioned is advised to get it direct from the companies, or from their own investment adviser. The New Money does not intend for this information to be used to inform an investment decision.

The New Money has been compensated by Conexeu Sciences for a media campaign, which affects our ability to be unbiased. The Principals of The New Money may buy or sell shares of the company without further notice. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities. The New Money and its principals and agents are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Always do your own research and consult with a licensed investment professional before making an investment.

This communication should not be used as a basis for making any investment. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy or Sell securities. No representation is being made that any stock trade will or is likely to achieve profits. Comparisons made to other featured companies or past performance is not indicative of future results.